|
| 產(chǎn)地 | France |
| 保存條件 | 2-8 ℃ |
| 品牌 | AntibodySystem |
| 貨號 | KDC90707 |
| 用途 | For Research Use Only. |
| 檢測方法 | Elisa |
| CAS編號 | |
| 保質(zhì)期 | 1 year |
| 適應(yīng)物種 | Ocaratuzumab |
| 檢測限 | 0.156 ug /ml |
| 數(shù)量 | 99999 |
| 包裝規(guī)格 | 96 assays |
| 標(biāo)記物 | Unconjugate |
| 純度 | 95%% |
| 樣本 | Plasma, Serum |
| 應(yīng)用 | Elisa |
| 是否進(jìn)口 | 否 |
KDC90707
The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.
Colorimetric
CV<20%
Plasma, Serum
Quantitative
0.156 μg/ml
0.31-5 μg/mL
80-120%
Ocaratuzumab
AME-133v, LY2469298, CAS: 1169956-08-4
Ocaratuzumab, previously known as AME-133v, is a humanized IgG1 type monoclonal antibody targeted at CD20 antigen, which is expressed on B-lymphocytes. Ocaratuzumab is a novel Fc-engineered monoclonal antibody designed by Applied Molecular Evolution in an attempt to induce effective antibody-dependent cell-mediated cytotoxicity (ADCC) at very low concentrations that may facilitate sub-cutaneous dosing. Libraries of antibody Fab fragment regions were generated with codon substituted variations of the antibody complementarity determining regions (CDRs) inserted into human antibody light and heavy chain germline frameworks. Then, the researchers expressed and selected mutants based on increased affinity for CD20. A variable region with increased binding activity for CD20 was selected and developed as ocaratuzumab. This drug is currently being developed by Mentrik Biotech and has been investigated in the trial for the treatment of cancer and autoimmune disorders. The pre-clinical trials of ocaratuzumab in follicular lymphoma was conducted in the United States (US) and Japan in phase I/II, and a Phase I trial was conducted in US rheumatoid arthritis patients. In addition, a phase III trial in relapsed follicular lymphoma patients is underway. Compared to rituximab, ocaratuzumab was shown to ocaratuzumab was shown to have 13 to 20 fold greater affinity for CD20 and 6 fold more potent ADCC in pre-clinical studies. The use of ocaratuzumab in other oncology and rheumatology indications has also been developed.
2-8 ℃
For Research Use Only.
Aiming to develop the most reliable bioreagents, AntibodySystem SAS was founded in 2019 in France by a team of professionals from top industrial companies and research institutes. The collective scientific and technical experiences in our team have brought breaking throughs in multiple product developments, including recombinant antibodies, recombinant proteins, biosimilar, RUO ELISA kits and other related products. By working with talented researchers and technicians, AntibodySystem continues to upgrade product qualities and lower the overall cost, offering accountable and affordable solutions for biolabs all over the world. Since its establishment, AntibodySystem has built long term and stable collaborations with academia, pharmaceutical industry, biotech companies and research hospitals, supporting their R&D by AntibodySystem's bioreagents with excellent data accuracy and reproducibility.
AntibodySystem由具有30多年蛋白抗體開發(fā)經(jīng)驗的 創(chuàng)立于法國,專注于生命科學(xué)和生物制藥領(lǐng)域研究,總部位于法國斯特拉斯堡市。AntibodySystem自主開發(fā)了高效、高產(chǎn)的真核重組表達(dá)系統(tǒng),利用該系統(tǒng)生產(chǎn)了高質(zhì)量的重組蛋白、抗體產(chǎn)品。目前產(chǎn)品包括藥物靶點蛋白以及對照抗體藥物、Invivo功能性抗體、SAA系列流式抗體、PEG抗體、磷酸化抗體、抗小分子抗體、ADA抗體、PK&ADA ELISA試劑盒。
普健生物作為AntibodySystem在亞洲區(qū)授權(quán) ,致力于為廣大科研工作者提供 的產(chǎn)品服務(wù)。
如果您對我們的產(chǎn)品感興趣,請聯(lián)系027-65279366。
以上產(chǎn)品僅用于科研,產(chǎn)品信息以產(chǎn)品 為準(zhǔn)
